After the closing on January 28, Maccura Biotechnology Co.Ltd(300463) fixed growth results were released. Gao Yi and Deng Xiaofeng’s two products were allocated about 270 million yuan in total.
Maccura Biotechnology Co.Ltd(300463) recently, the stock price has continued to decline, falling by 28.97% in the past nine trading days. The closing price on January 28 has fallen by nearly 35% from the intraday high of 38.24 yuan on January 17, and has fallen below the fixed increase price of 28.11 yuan.
Gao Yi, Deng Xiaofeng, 270 million yuan participation in fixed growth
On January 28, Maccura Biotechnology Co.Ltd(300463) released the report on the issuance of shares to specific objects and listing on the gem, and the fixed increase results surfaced.
The fixed increase price is 28.11 yuan / share, the number of shares issued is 56 million, and the total amount of funds raised is 1.574 billion yuan. The report shows that the issuing object is finally determined as 17, and many well-known investment institutions are listed.
Image source: Announcement
In terms of public offering, CAITONG fund was allocated 298 million yuan, Nord fund was allocated 84.1988 million yuan, and Xingzheng Global Fund was allocated 85.611 million yuan. In terms of private placement, the two funds managed by Gao Yi assets Deng Xiaofeng, Gao Yi Xiaofeng No. 2 letter fund and Gao Yi Xiaofeng No. 1 Ruiyuan fund, were allocated a total of nearly 270 million yuan.
The announcement shows that before the fixed increase, as of December 31, 2021, Gao yixiaofeng No. 2 letter fund had held Maccura Biotechnology Co.Ltd(300463) 1.38% of the shares, ranking the eighth largest shareholder. After the fixed increase, the fund is still the eighth largest shareholder, and the shareholding ratio is further increased to 2.41%.
Gao Yi asset Deng Xiaofeng has frequently participated in fixed growth recently. Previously, Yonyou Network Technology Co.Ltd(600588) published fixed growth results showed that the two funds managed by Deng Xiaofeng were allocated nearly 400 million yuan in total.
performance increase in 2021
Maccura Biotechnology Co.Ltd(300463) the current market value is about 13.873 billion yuan. Why is this small market value company favored by Deng Xiaofeng?
According to public information, Maccura Biotechnology Co.Ltd(300463) is a professional R & D and production enterprise of clinical in vitro diagnostic products in China. It was founded in 1994 and went public in May 2015. The company has always focused on the research, production, sales and service of in vitro diagnostic products, and has established a product technology development platform for clinical biochemistry, luminescence immunity, rapid diagnosis, thrombosis and hemostasis, and molecular diagnosis.
Since its listing, the operating revenue of Maccura Biotechnology Co.Ltd(300463) has increased steadily from 1.065 billion yuan in 2015 to 3.704 billion yuan in 2020. On January 28, Maccura Biotechnology Co.Ltd(300463) released the performance forecast. It is estimated that the net profit attributable to the parent company in 2021 will be 913 million yuan – 992 million yuan, with a year-on-year increase of 15% – 25%.
Image source: Announcement
For performance changes, the company said in the announcement that under the dual influence of covid-19 epidemic and policies in 2021, the upstream and downstream of in vitro diagnosis industry are facing great pressure and uncertainty, but challenges always coexist with opportunities. This year, the company took the strategic path of independent product development more firmly. The management actively promoted the development process from “whole product line and whole industrial chain” layout to “serialization, systematization, automation and autonomy” of products, continuously increased R & D investment, supplemented and improved the types of independent products, and continuously improved its competitiveness in products, technologies, costs and services, Multi platform independent products have realized comprehensive laboratory automation solutions.
The announcement shows that the company’s revenue from independent products has maintained a steady growth, and the growth rate and revenue share have exceeded that of agency products. Among them, the revenue growth rate of molecular, immunization and temporary inspection platform products has exceeded 30%; With the increase of R & D investment and de agency, the operating efficiency of the company has been continuously improved.
However, since January 18, Maccura Biotechnology Co.Ltd(300463) share price has continued to decline. As of the closing on January 28, Maccura Biotechnology Co.Ltd(300463) closed at 24.93 yuan / share, down nearly 35% from the intraday high of 38.24 yuan on January 17 and 11.31% from the fixed increase price of 28.11 yuan.
